EUCTR2008-003861-17-SE
进行中（未招募）
不适用
A double-blind, randomised, placebo controlled, phase I/IIa dose escalation study to investigate the safety and tolerability of Oralgen Birch Pollen immunotherapy in patients with allergic rhinoconjunctivitis
Artu Biologicals Europe B.V.0 个研究点2008年6月24日
概览
- 阶段
- 不适用
- 干预措施
- 未指定
- 疾病 / 适应症
- Allergic rhinoconjunctivitis
- 发起方
- Artu Biologicals Europe B.V.
- 状态
- 进行中（未招募）
- 最后更新
- 14年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •\- Male and female between 18 and 60 years of age (inclusive).
- •\- History of birch pollen induced allergy with moderate to severe rhinoconjunctivitis symptoms for at least two seasons.
- •\- RRTSS of greater than or equal to 10 out of a maximal score of 18
- •\- Birch pollen specific RAST of at least class 2\.
- •\- Positive skin prick test (i.e. wheal diameter equal to or more than (\=) 3 mm larger than the diluent control) for birch pollen.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range
- •F.1\.3 Elderly (\>\=65 years) no
排除标准
- •\- Other clinically relevant allergies (perennial or seasonal) that could potentially interfere with the patient's study treatment schedule or assessments. Patients with allergic rhinoconjunctivitis due to allergens to which the patient is not exposed to during the study are allowed into the study.
- •\- Use of oral steroids within 12 weeks before the screening visit.
- •\- Treatment with beta\-blockers or continuous inhalsed or systemic corticosteroid therapy.
- •\- Previous immunotherapy treatment with tree pollen extracts within the last five years or immunotherapy with any other allergen extract within the last two years.
结局指标
主要结局
未指定
相似试验
进行中（未招募）
不适用
A double-blind, randomised, placebo controlled, phase I/IIa dose escalation study to investigate the safety and the effect of different doses of Oralgen House Dust Mite in patients with house dust mite induced allergic rhinoconjunctivitisEUCTR2008-003879-49-GBArtu Biologicals Europe B.V.
进行中（未招募）
不适用
Fulvestrant +/- vandetanib in advanced aromatase inhibitor resistant breast cancer.Metastatic breast cancer that has become resistant to aromatase inhibitor therapyTherapeutic area: Diseases [C] - Cancer [C04]EUCTR2014-001208-23-GBVelindre NHS Trust
进行中（未招募）
1 期
Pirfenidone in heart failure with preserved ejection fractioHeart failure with preserved ejection fraction (HFpEF)MedDRA version: 19.0Level: LLTClassification code 10069211Term: Diastolic heart failureSystem Organ Class: 100000004849MedDRA version: 19.0Level: LLTClassification code 10019279Term: Heart failureSystem Organ Class: 100000004849Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2016-002647-42-GBniversity Hospital of South Manchester
已完成
不适用
Phase I study to assess the pharmacokinetics and pharmacodynamics of macitentan in Korean healthy male subjectsDiseases of the circulatory systemKCT0000326Actelion Pharmaceuticals Korea30
进行中（未招募）
1 期
A placebo-controlled study to evaluate the safety, tolerability, biochemical and physiologic effects of two infusions of escalating doses of TPM502 in adults diagnosed with celiac diseaseEUCTR2022-001656-41-FITopas Therapeutics GmbH42